ICP-022 is a novel selective BTK inhibitor which is in clinical studies for efficacy and safety in a broad pivotal trials in China to treat B cell malignancies.

•    BTK (Bruton Tyrosine Kinase) is a key molecule for signaling   of B cell antigen receptor and cytokine receptor pathways. It is important for  B cell activation, chemotaxis and adhesion through BCR  pathways, and play a critical role for B cell proliferation, differentiation and apoptosis. Selective BTK inhibitors have been demonstrated effective for B cell malignancies and auto-immune diseases.

•    B cell lymphoma is a leading hematological malignancy world-wide. ICP - 022 has   excellent  kinase selectivity in vitro and good anti-tumor activity in vivo.GLP tox study demonstrated good safety profile and large therapeutic window.

•    Autoimmune diseases and tumors remain to be great challenges for  medical research. Due to the complexicity and heterogeneity, autoimmune diseases need more potent and safety therapies for long term uses. ICP-022, an oral drug, offers a completely novel therapeutic option with good efficacy and safety  in preclinical studies.